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Abstract
The Cks1 component of the SCF
Skp2 complex is necessary for p27
Kip1 ubiquitylation and degradation. Cks1 expression is
elevated in various B cell malignancies including Burkitt lymphoma and multiple myeloma. We have previously shown that
loss of Cks1 results in elevated p27
Kip1 levels and delayed tumor development in a mouse model of Myc-induced B cell
lymphoma. Surprisingly, loss of Skp2 in the same mouse model also resulted in elevated p27
Kip1 levels but exhibited no
impact on tumor onset. This raises the possibility that Cks1 could have other oncogenic activities than suppressing p27
Kip1.
To challenge this notion we have targeted overexpression of Cks1 to B cells using a conditional retroviral bone marrow
transduction-transplantation system. Despite potent ectopic overexpression, Cks1 was unable to promote B cell
hyperproliferation or B cell malignancies, indicating that Cks1 is not oncogenic when overexpressed in B cells. Since
Skp2 overexpression can drive T-cell tumorigenesis or other cancers we also widened the quest for oncogenic activity of
Cks1 by ubiquitously expressing Cks1 in hematopoetic progenitors. At variance with c-Myc overexpression, which caused
acute myeloid leukemia, Cks1 overexpression did not induce myeloproliferation or leukemia. Therefore, despite being
associated with a poor prognosis in various malignancies, sole Cks1 expression is insufficient to induce lymphoma or a
myeloproliferative disease in vivo.
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Introduction
A central regulatory protein that exerts functions at the G1-S
and G2-M transition of the cell cycle is the Cyclin-dependent
kinase (Cdk) inhibitor p27
Kip1 [1,2]. Thus, complete loss of
p27
Kip1 leads to increased cell proliferation and overexpression of
p27
Kip1 arrests cells in G1 [3–6]. Because of the elemental role of
p27
Kip1 for ordered cell proliferation it also functions as a tumor
suppressor and can be used as a prognostic factor in various
malignancies [1,7].
The regulation of p27
Kip1 expression occurs mainly at the post-
translational level. The current model involves phosphorylation of
p27
Kip1 at threonine 187 (T187) during G1 by Cyclin E/A-Cdk2
complexes, which marks p27
Kip1 for recognition by the E3
ubiquitin ligase SCF
Skp2 [1,8–10]. SCF
Skp2 requires the presence
of the small protein Cyclin-dependent kinase subunit 1 (Cks1) that
constitutes a part of the substrate binding surface, to allow efficient
ubiquitylation of T187-phosphorylated p27
Kip1 [11,12]. Tissues
from mice lacking Cks1 accumulate p27
Kip1 and exhibit prolifer-
ative defects [13]. Accordingly, Cks12/2 mice exhibit a small
body size, resembling the size phenotype also seen in Skp22/2
mice [14]. Cks12/2 epithelial tissues however lack additional
defects such as enlarged nuclei with polyploidy [14]. Cks1 is
furthermore involved in Cdk activation and acts as a targeting
protein for Cdks [15,16], and as an essential regulator of mitosis.
For example, Cks proteins are required for ubiquitylation and
degradation of Cyclin A complexed with Cdc20 in pre-anaphase,
which is required for mitotic progression [17].
The human CKS1B gene is located in a region of chromosome
1q that is frequently amplified in cancer. Cks1b has been found
overexpressed in breast cancer [18,19], as well as in a broad
spectrum of other human malignancies [20–24]. In multiple
myeloma (MM), an aggressive bone marrow cancer originating
from terminally differentiated B cells, CKS1B is frequently
overexpressed. Recent data showed that chromosome 1q21
amplification and elevated CKS1B protein expression were
strongly correlated, and that nuclear CKS1B protein expression
inversely correlates with p27
Kip1 immunostaining. Importantly,
CKS1B expression was associated with a shorter overall survival
[25,26].
We have previously shown that loss of Cks1 and Skp2 results in
elevated levels of p27
Kip1 in B cells, but that only loss of Cks1
resulted in a significant delay in lymphomagenesis of Em-Myc
transgenic mice [27,28]. We therefore hypothesized that Cks1
could have other oncogenic functions, possibly not related to its
function in the SCF
Skp2 complex. To address this we applied a
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pan-hematopoietic compartment of mice.
Results
Cks1 is overexpressed in various B cell malignancies
In Em-Myc mice, a model of the human Burkitt-Lymphoma
[29], loss of Cks1 leads to a profound delay in lymphoma onset
[27]. To investigate if lymphoid malignancies are associated with
increased CKS1B transcript levels, we mined a publicly available
gene expression array database (www.oncomine.org). We found
the highest CKS1B transcript levels in multiple myeloma, and
CKS1B was also highly expressed in Burkitt lymphoma, diffuse
large B cell lymphoma, but not in chronic lymphocytic leukemia
(CLL), a lymphoid disorder with a usually indolent clinical course
and low proliferative activity, at least in the peripheral blood
(Figure S1). Thus, various aggressive B cell malignancies are
characterized by elevated CKS1B transcript levels.
Motivated by the clinical significance of Cks1 overexpression,
we decided to continue our studies on the functions of Cks1 in B
cell malignancies. One of the unanswered questions in our
previous study [27] was if Cks1 loss only impacted cell
proliferation in precancerous B cells or if the reduced proliferation
was maintained in lymphomas that arose in Em-Myc mice. To
address this we derived primary Myc-driven lymphoma cells of
Cks1+/+ or Cks12/2 genotype that were established in vitro. As
expected Cks12/2 lymphomas showed highly elevated p27
Kip1
protein levels with unaffected p27
Kip1 transcript levels when
cultured in vitro (Figure 1A and data not shown). Importantly, loss
of Cks1 resulted in a significant growth reduction of the cultured
lymphoma cells as assessed by BrdU incorporation and cell
counting (Figure 1B, C). Furthermore, when grown in methylcel-
lulose not supported by growths factors, we found an impaired
formation of lymphoma colonies upon Cks1 loss (Figure 1D).
Thus, even in established Myc-driven lymphomas grown in vitro,
there is a marked impact on proliferation caused by Cks1 loss.
Cks1 overexpression targeted to B cells is not sufficient
to induce lymphoma
The fact that tumor cells are unable to circumvent the
dependence on Cks1 suggested that Cks1 could have broad effects
on the cell cycle, or that the tumor cells are addicted to high levels
of Cks1, akin to oncogene addiction. However, the likelihood that
the general effects on cell cycle would be connected to p27
Kip1 was
hampered by the fact that Skp2 loss did not impact lymphoma-
genesis in Em-Myc mice, despite elevated p27
Kip1 levels [28].
Therefore, to directly assess the putative oncogenic role of Cks1 in
B cell lymphoma in vivo we cloned the Cks1 coding sequence into a
retroviral expression plasmid that allows Cre-mediated excision of
a stop signal (Figure S2A, described in detail in Miething et al.,
submitted). To test whether Cre expression would indeed result in
Cks1 overexpression we used NIH-3T3 cells expressing either
MSCV-Cre-IRES-Puro (Cre) or Puromycin resistance alone
(Puro) that were infected with MSCV-lox-stop-lox-Cks1-IRES-
GFP or control virus. Elevated Cks1 protein levels were detected
in Cre-expressing NIH-3T3 cells but not in control cells,
indicating the functionality of the Cre-medited excision which
leads to Cks1 protein expression (Figure 2A). Next, to test the
transforming activity of Cks1 in vivo, we used a retroviral
transduction-transplantation model [30]. Upon viral infection of
CD19-Cre transgenic 5-FU mobilized donor bone marrow, the
graft that was injected into the tail vein to reconstitute lethally
irradiated recipients (Figure 2B). Two independent transplanta-
tions were established: one with low percentage (,20%) of GFP
infected graft cells and one with high percentage of GFP positivity
in the graft (,50%). The engraftment of both experiments was
characterized by high GFP positivity in B cells after 28 days post
transplantation (Fig. 2C). To ensure that the retroviral expression
plasmid indeed resulted in a B cell-targeted expression of Cks1 we
verified elevated mRNA levels and protein levels in Cks-
overexpressing B cells (Figure 2D, E). To analyze whether Cks1
expression in B cells would lead to a lymphoproliferation, blood
samples were taken at regular intervals to examine changes in
WBC counts and of GFP positivity in the transplanted mice. Both
groups, the Cks1 group and the control group, showed heteroge-
neous patterns of GFP-positive B cells. Some animals had a very
high amount of GFP positive cells during their life span and others
showed reduced GFP positivity over time (Figure 3A). Important-
ly, WBC counts for both groups stayed in fairly normal range (data
not shown). The analysis of mice with Cks1 overexpression
targeted to B cells showed no difference in comparison to control
mice with regards to either B cell frequency, a selective
proliferation advantage or disadvantage of B cells expressing
Cks1, or an altered B cell differentiation pattern (Figure S3).
Importantly, there was no onset of either B cell proliferative
disease or B cell lymphoma in the mice overexpressing Cks1 in the
B cell compartment during the observation period. Eventually, the
animals in both groups succumbed to irradiation-induced malig-
nancies (Figure 3D; median survival: Stop-Cks1-GFP group, 410
days; Stop-GFP control group, 336.5 days). Post mortem analysis of
the bone marrow, lymph nodes and spleen showed same amounts
of GFP positivity and GFP positive B cells in the Cks1 group
versus control (Figure 3B, C and data not shown). Thus, B cell-
targeted overexpression of Cks1 could not induce a lymphoma or
lymphoproliferative disease during the observation period.
Cks1 regulates proliferation in oncogene-induced AML
but is not sufficient to mediate myeloproliferation
High Cks1 levels are a characteristic of various cancers and are
also associated with low levels of the tumor suppressor p27
Kip1
[25,31]. To test whether Cks1 would induce malignancy when
ubiquitously overexpressed in the bone marrow of lethally
irradiated recipient mice we again performed bone marrow
transplantations in a transduction-transplantation model, this time
with a constitutive retroviral expression plasmid (Figure S2B). We
achieved highly elevated ectopic Cks1 transcript and protein levels
in the bone marrow of recipient mice (tested 160 days post
transplantation, Figure 4A and after indisposition and sacrifice
4B). This resulted in an expansion of the myeloid compartment in
bone marrow and spleen (Figure 4C) but we did not detect tumor
induction upon ectopic Cks1 overexpression. Rather, both groups
of mice succumbed to irradiation-induced secondary malignancies
not associated with hematopoietic disease (Figure 4D, E, and data
not shown).
At variance with Cks1 overexpression, c-Myc overexpression
using the same system resulted in acute myeloid leukemia
(Figure 4D, E). To reveal if loss of Cks1 would impact this
disease, we overexpressed c-Myc in hematopoietic progenitors
from wild type and Cks1 knockout mice (Figure 5A). To rule out
effects of p27
Kip1 we also transduced bone marrow cells from
p27
Kip1 knockout and Cks1;p27
Kip1 double knockout mice with the
c-Myc retrovirus. As expected from the studies in the Em-Myc mice
[27] loss of Cks1 resulted in a significant reduction of the
percentage of premalignant Gr1/CD11b positive myeloid cells in
S phase (Figure 5B), confirming that Cks1 is required to allow the
full proliferative advantage conferred by the Myc oncoprotein.
However, in the absence of p27
Kip1 this proliferative deficiency
was completely reverted as shown in Cks1;p27
Kip1 double knockout
Cks1 Overexpression Is Not Oncogenic
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(Figure 5B). Surprisingly though, the effects on cell proliferation of
either loss of Cks1 or its reversal by concomitant loss of p27
Kip1
had no significant impact on the disease onset in the highly
aggressive Myc-AML model (Figure 5C).
Discussion
Cks1 is an essential component of the SCF
Skp2 complex that
controls among others the cell cycle inhibitor p27
Kip1 [32,33]. The
function of Cks1 and Skp2 in lymphoma development is however
not clearly understood as the correlative data from several studies
indicates that sole accumulation of p27
Kip1 is not the mechanistic
explanation for the observed effects. First, only Cks1 loss, but not
Skp2 loss, significantly delays lymphomagenesis, despite that both
knockout mice have elevated p27
Kip1 levels in the B cell
compartment [27,28], and despite the observation that p27
Kip1
loss dramatically accelerates Myc-induced lymphomagenesis [34].
Skp2 loss does however impact tumorigenesis in a Pten-deletion
model [35]. Second, overexpression of one of the SCF
Skp2
complex components (Cks1 or Skp2) may not necessarily result
in elevated activity of the whole complex and suppression of
p27
Kip1 levels. (see Figure 4B, and [36]). Still, Skp2 overexpression
targeted to the prostate results in tumorigenesis [37]. Third, we
can rescue a proliferation defect exerted by Cks1 loss in
premalignant myeloid cells by removing p27
Kip1, but changes in
proliferation does not impact AML latency.
In this study we addressed the question whether or not Cks1 is
an oncogene in the hematopoietic system. Although we cannot
demonstrate that Cks1 itself is oncogenic, we found that Cks1
constitutes an important circuit in oncogene-driven proliferation.
In this scenario, Cks1’s major effect is to suppress p27
Kip1 levels
[13] and therefore concurrent loss of p27
Kip1 results in the full
reconstitution of Myc-induced proliferation in myeloid cells.
Moreover, our data also suggests that Cks1 is more important
for B cell lymphomagenesis than for AML development. Although
the effects of Cks1 loss on cell proliferation in premalignant
myeloid cells was slightly weaker than in B cell lymphomas, our
results suggest a disconnect between effects on cell cycle
progression and effects on tumorigenesis. If so, it is plausible that
Cks1 is involved in both these processes.
Elevated Cks1 levels have been found in various malignancies
including aggressive lymphomas, and Cks1 transcription has been
shown upon oncogene overexpression [27]. In an effort to link
elevated Cks1 levels and oncogenesis recent work established that
Cks1 overexpression and binding of Cks1 to Cdk2 results in
overriding the intra-S-phase checkpoint triggered by activated
oncogenes. Cks protein overexpression thus likely constitutes one
mechanism whereby premalignant cells can circumvent this DNA
damage response barrier, conferring a proliferative advantage
Figure 1. Cks1-deficient Em-Myc lymphomas display reduced proliferation and colony formation in vitro. Primary Myc-induced
lymphoma cells of the indicated Cks1 genotype were cultured in vitro until they were independent of stromal cell support. A, Immunoblot analysis of
Myc, Cks1 and p27
Kip1 protein levels, representative analysis. B, Left panel: Representative flow cytometry dot plot images of in vitro BrdU-labelled
lymphoma cells of the indicated Cks1 genotype. Right panel: the bars represent the mean 6 standard error of the mean of the indicated cell cycle
phase. * indicates p,0.05. C, Growth curve of in vitro cultured lymphoma cells of the indicated Cks1 genotype. Cells were replated daily and the
growth curve calculated based on the -fold increase in cell number starting with 1610
6 cells (day 1). The graph represents the mean 6 standard
deviation from 3 independent experiments. * indicates p,0.05. D, 200 Em-Myc lymphoma cells of the indicated Cks1 genotype were plated in
methylcellulose. The number of colonies was counted on day 7. The graph represents the mean 6 standard deviation from 2 independent
experiments.
doi:10.1371/journal.pone.0037433.g001
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development [38]. In conclusion, Cks1 may serve several functions
in supporting tumor progression: first, to allow cells to escape the
DNA damage response that is triggered by oncogene activation
and conditions of replicative stress. Second, to suppress p27
Kip1
levels which allows increased tumor proliferation, a finding that
corresponds well with the negative prognostic impact of low tumor
cell p27
Kip1 levels [1,34]. Furthermore, and probably highly
important for the outcome of tumor patients, p27
Kip1 has been
shown to inhibit tumor cell invasion [39]. In line with this finding,
the absence of Cks1 resulted in p27
Kip1 accumulation and loss of
lymphoma dissemination [27].
Materials and Methods
Mice and tumor surveillance
Cks1-null mice (mixed background) [13] were bred with Em-Myc
transgenic mice (C57BL/6) [29]. F1 offspring were then bred to
gain Cks1+/+ and Cks12/2 Em-Myc transgenic littermates to
obtain primary lymphomas. Animals were observed for signs of
morbidity and tumor development. Tumors were harvested after
sacrifice of mice and cells were frozen viable. Cks1-null mice and
p27+/2 mice [4] were bred to obtain Cks12/2;p272/2 mice.
Recipient C57/Bl6 mice for transplantation experiments were
purchased from Charles River Laboratories (Sulzfeld, Germany)
or Harlan Laboratories (Eystrup, Germany) and were monitored
for disease by serial peripheral blood analysis and daily physical
Figure 2. B cell-specific Cks1 overexpression results in elevated Cks1 protein levels. A, Immunoblot analysis of Cre-mediated conditional
expression of Cks1 in retrovirally infected NIH-3T3 shows the tightness of the translational stop-cassette. Retroviral infection was performed 3 times in
12 hour intervals with 8 mg/ml polybrene. B, Depiction of the murine bone marrow retroviral transduction-transplantation model. 5FU-stimulated
bone marrow cells from CD19-Cre transgenic mice were infected 4 times with retrovirus and then intravenously injected into lethally irradiated wild
type (wt) recipient mice. C, Flow cytometric analysis of engraftment of GFP-positive B cells in the peripheral blood 28 days after bone marrow
transplantation. Left panel: Histogram upon B220 staining. Right panel: Results of two different transplantations are combined. The bars represent the
mean 6 standard error (n=7 mice for Stop-GFP, n=9 for Stop-Cks1-GFP). One experiment was performed with 2610
6 transplanted cells and an
infection rate of 15% (GFP positivity, n=4 or 5 recipient mice), and one with 1610
6 cells and an infection rate of 45% (GFP positivity, n=2 or 3
recipient mice). D, realtime PCR analysis of Cks1 transcript levels in the indicated cells. Stop-GFP (n=2), Stop-Cks1-GFP (n=3). The bars represent the
mean 6 standard deviation. E, Immunoblot anaylysis of Cks1 protein levels in B220+GFP+ B cells. The B cells were FACS-sorted from n=6 mice of
each of the indicated treatment groups 50 days after transplantation.
doi:10.1371/journal.pone.0037433.g002
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approved by the responsible regional authorities (#55.2-1-54-
2531-48-08, Regierung von Oberbayern).
Cell culture
Em-Myc lymphoma cells were established from single cell
suspensions of tumors arising in Em-Myc mice. Lymphomas were
cocultured on stromal cells (cell line EL08-1D2) [40] in RPMI
(Gibco life technologies, Darmstadt, Germany) supplemented with
10% FCS (PAA Laboratories, Pasching, Austria), 1% Pen/Strep,
1% L-Glutamin, 0.1% Mercaptoethanol (all from gibco life
technologies) and 10 ng/ml IL-7 (mIL7, R&D Systems). When
steady growth conditions were achieved lymphoma cells were
deprived from EL08 cells and IL-7. Phoenix ecotopic helper-free
retroviral producer cells (G. Nolan, Stanford, CA, USA) and
NIH/3T3 cells (DSMZ, Braunschweig, Germany) were main-
tained in DMEM (Gibco life technologies) supplemented with
10% FCS. Colony formation analysis was done with MethoCult
M3234 (Stem Cell Technologies) for 7 days. Cells were cultured at
37uC with 5% CO2.
Figure 3. Targeted Cks1 overexpression is not sufficient to induce B cell lymphoproliferation or lymphoma. Data from two
experiments (see Figure 2) are combined. One experiment with 2610
6 transplanted cells and an infection rate of 15% (n=4 or 5 recipient mice) and
one with 1610
6 cells and an infection rate of 45% (n=2 or 3 recipient mice). A, Flow cytometric analysis of the percentage of GFP-positive B cells.
Leucocytes were gated on B220+ cells. The analysis shows a divergence in the groups, some animals loose GFP positivity in the B cell compartment
over time irrespective of the transduction efficiency. B, Left panel: Flow cytometric results of the bone marrow (BM) and spleen (S) for GFP positivity
(of all cells, after lysis of erythrocytes). Right panel: percentage of GFP-positive cells in the B220 compartment of bone marrow (BM) and spleen (S).
The analysis was performed on the day of indisposition and sacrifice. C, Representative images of flow cytometric analysis of GFP-positive B cells in
the bone marrow. The genetic group is indicated. D, Survival of the CD19-Cre;Stop-Cks1-GFP group (median: 444 days) was identical to the survival of
the CD19-Cre;Stop-GFP group (median: 391 days). All mice died from irradiation induced reasons but not B cell lymphoma.
doi:10.1371/journal.pone.0037433.g003
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MSCV-c-Myc-IRES-GFP was a gift of C. Schmitt (Berlin,
Germany). MSCV-Cks1-IRES-GFP was cloned by digesting the
MSCV-IRES-GFP plasmid with EcoRI and BglII (Fermentas, St.
Leon-Roth, Germany) following a PCR for Cks1 with primers
containing overhangs for EcoRI and BglII restriction (Omniscript
RT Kit, Quiagen, Hilden, Germany). Ligation was performed
using the Quick T4 DNA Ligase (New England Biolabs, Ipswich,
England). The Stop element in MSCV-Stop-GFP contains the
translational stop-codon ‘TGA’ in each reading frame leading to a
termination of translation. It is flanked by loxP sites allowing a
Cre-mediated excision (described in detail in Mieting et al.,
Figure 4. Ubiquitous Cks1 overexpression in the bone marrow is not sufficient to induce myeloproliferative disease or leukemia.
4610
6 GFP-positive cells were transplanted with an infection rate of 30%. A, Cks1 mRNA levels in the indicated bone marrow subsets of transplanted
mice were analyzed by realtime PCR at day 160 after transplantation. Shown is the relative expression of Cks1 as compared to the B cell expression of
the GFP mice as a control sample set at 1. GFP group: n=2; Cks1-GFP group: n=3. The bars represent the mean relative expression 6 standard
deviation. realtime PCR was performed in duplicates. B, Immunoblot analysis of the bone marrow of transplanted mice on the day of indisposition
and sacrifice. C, The left panel shows the GFP positivity of the bone marrow (BM) and spleen (S). The three right panels show the percentages of B-, T-
and myeloid cells. D, Representative flow cytometric dot blot images of the myeloid cell compartment of GFP, Cks1-GFP and Myc-GFP animals on the
day of their sacrifice. E, Survival analysis of lethally irradiated recipient mice that were transplanted with GFP, Cks1-GFP or Myc-GFP infected bone
marrow. None of the GFP or Cks1-GFP mice died of leukemia, while all Myc-GFP mice succumbed to AML. Median survival: GFP group, 469 days; Cks1-
GFP group, 541.5 days; Myc-GFP group, 52 days. Only the survival of Myc-GFP group is significantly different from the other groups.
doi:10.1371/journal.pone.0037433.g004
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First using PCR primers with EcoRI and BglII overhangs to excise
the Stop construct out of the MSCV-Stop-GFP plasmid and
ligation into MSCV-IRES-GFP. Secondly we performed a PCR
for Cks1 with BglII and XhoI overhangs following ligation.
Generation of retrovirus and bone marrow
transplantation
Retrovirus was obtained through transient infection of Phoenix
E cells with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. NIH/3T3 cells were
infected three times in 12 h intervals with retrovirus, supplement-
ed with 8 mg/ml Polybrene (Sigma-Aldrich, Milwaukee, WI,
USA). Bone marrow infection and transplantation was performed
as described earlier [30]. Lethally irradiated (900 rad) female C57/
Bl6 mice were transplanted with 1610
6 to 4610
6 GFP+ cells with
infection rates from 15% up to 50% measured as GFP positive
cells. Transplanted cells and infection rates were kept at same rates
in single experiments.
Flow cytometry and cell sorting
Antibodies for flow cytometry were purchased from BD
Pharmingen or eBioscience (San Diego, CA, USA). Cells were
stained in PBS (PAA, Pasching, Austria) containing 0.5% BSA
(Roth, Karlsruhe, Germany) and antibodies were used 1 ml/1610
6
cells. BrdU assays were performed using the BrdU Flow kit (BD
Pharmingen, San Diego, CA) according to the manufacturer’s
instructions. Analysis was performed with the Cyan ADP Lx P8
(Coulter-Cytomation; Beckman-Coulter, Krefeld, Germany), flow
cytometric cell sorting with the MoFlo (Cytomation, Beckman
Coulter).
RNA preparation and analysis, real-time PCR
For reverse transcriptase quantitative PCR (qRT-PCR), RNA
was prepared from flow cytometry-sorted bone marrow cells using
the Dynabeads mRNA Direct Micro kit (Dynal, Oslo, Norway).
cDNA was prepared using the Omniscript RT kit (Quiagen,
Hilden, Germany). qRT-PCR was performed using an Applied
Biosystems 7900HT (Carlsbad, CA) and the Power Sybr Green kit
(Applied biosystems, Warrington, UK). Data analyses were
performed with the DCt method, where ubiquitin served as the
internal control. Sequences for primers are available from the
authors upon request.
Immunoblotting
Cell lysis for immunoblotting was performed with lysis buffer
containing 50 mM Hepes (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 2.5 mM EGTA, 0.1% Tween-20 (all from Sigma-Aldrich,
Deisenhofen, Germany) and protease inhibitors (Roche, Mann-
heim, Germany) followed by sonification [41]. After SDS-PAGE,
proteins were transferred to PVDF membranes (Millipore
Corporation Billerica, MA, USA) and probed with antibody.
Anti-Cks1 was purchased from Invitrogen (Frederick, MD, USA),
anti c-Myc from Santa Cruz Biotechnology Inc. (Santa Cruz, CA),
Figure 5. Cks1 regulates proliferation in oncogene-induced AML by suppressing p27
Kip1.A , 5-FU-mobilized bone morrow from mice of
the indicated genotype was infected with Myc-GFP virus and 2610
6 GFP-positive cells were transplanted with an infection rate of about 40% into
lethally irradiated recipients. Immunoblot analysis of the indicated proteins was performed 3 weeks after transplantation. B, Flow cytometric anti-
BrdU staining of GFP-positive Gr1/CD11b-positive bone marrow cells. 1 mg BrdU/g body weight was intraperitoneally injected 12 hours before bone
marrow harvest. The bars represent the mean 6 standard deviation of n=3 or 5 individual mice per genotype. C, Survival curve of mice transplanted
with Myc-GFP-infected bone marrow of the indicated Cks1 and p27
Kip1 genotype. All mice died from AML. The median survival is not significantly
different between the genotypes.
doi:10.1371/journal.pone.0037433.g005
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Kip1 from BD Transduction Laboratories, and anti-ß-
Actin (Actin) from Sigma-Aldrich (St. Louis, MO).
Statistical analysis
Statistical analyses were performed using the statistical functions
of Excel or GraphPad Prism (GraphPad Software, La Jolla, CA).
The bars shown represent the mean 6 standard deviation (SD) or
standard error of the mean (SEM). All statistical analyses were t-
tests. Only p values,0.05 were considered statistically significant.
Supporting Information
Figure S1 Elevated CKS1B transcript levels in various B
lymphoid malignancies. A public database (www.oncomine.
com) was searched for studies that compare CKS1B transcript
levels in control tissue and samples from patients with B cell
malignancies [35]. Shown is the log2 median-centered relative
intensity of expression for CKS1B [reporter: 37347_at].
(PDF)
Figure S2 Cks1 expression plasmids used. A, Schematic
depiction of the lox-stop-lox plasmid used (Stop-Cks1-GFP). The
control plasmid used is labeled Stop-GFP in all Figures. B,
Schematic depiction of the expression plasmid used (Cks1-GFP)
for ubiquitous expression. The control plasmid used is labelled
GFP, the MSCV-Myc-IRES-GFP plasmid is labelled Myc-GFP.
(PDF)
Figure S3 B cell-specific overexpression of Cks1 does
not lead to a change in B cell frequency, cell cycle state,
or differentiation. Experiments were performed 28 days after
bone marrow transplantation of 2610
6 GFP-positive cells and an
infection efficiency of about 40%. Left panel: Flow cytometric
detection of the percentage of Cks1 overexpressing B cells versus
controls in the lymphoid compartment of the bone marrow using
GFP as a marker. Middle panel: Flow cytometric anti-BrdU
staining of GFP-positive B220+ B cells. 1 mg BrdU/g body weight
was intraperitoneally injected 12 hours before bone marrow
harvest. The bars represent the mean 6 standard deviation of
n=7 or n=6 individual mice per group. Right panel: Flow
cytometric measurement of the differentiation pattern of Cks1
overexpressing B cells versus controls (GFP+, B220+ cells).
(PDF)
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